Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.
Cancer Med
; 12(15): 16066-16075, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37489066
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Esophageal Neoplasms
/
Esophageal Squamous Cell Carcinoma
Type of study:
Clinical_trials
/
Etiology_studies
Limits:
Adult
/
Aged
/
Humans
Language:
En
Journal:
Cancer Med
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: